HER2 receptor, which is frequently overexpressed in breast cancer, is a preferential partner of EGFR and the formation of EGFR-HER2 heterodimers potentiates EGFR function by increasing EGF binding affinity, stabilizing and recycling the receptor on the membrane, and expanding the repertoire of intracellular signaling responses [95]. The gene discussed is ERBB2; the disease is breast carcinoma.